BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 27, 2007
 |  BC Extra  |  Clinical News

CellCept misses lupus endpoint

Aspreva (TSX:ASV; ASPV) and partner Roche (SWX:ROG) said CellCept missed the primary endpoint of a response rate that was superior to IV cyclophosphamide in the 24-week, open-label induction phase of a Phase III...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >